Journal
RHEUMATOLOGY
Volume 60, Issue -, Pages II17-II23Publisher
OXFORD UNIV PRESS
DOI: 10.1093/rheumatology/keaa823
Keywords
rheumatoid arthritis; JAK1 inhibitors; upadacitinb; filgotinib; efficacy
Categories
Funding
- Gilead
Ask authors/readers for more resources
Upadacitinib and filgotinib, two JAK1 selective drugs, have shown rapid improvements in disease activity, function, and patient reported outcomes in extensive phase III clinical trials for rheumatoid arthritis. With upadacitinib already approved in most markets globally, the studies focused on demonstrating therapeutic efficacy and safety of these drugs in RA treatment.
Upadacitinib and filgotinib, two JAK1 selective drugs have undergone extensive phase III clinical trials in RA and have demonstrated rapid improvements in disease activity, function and patient reported outcomes. Six global phase III randomized controlled clinical trials (SELECT phase III program) evaluated the efficacy and safety of upadacitinib and four clinical phase III trials (the FINCH program) evaluated the efficacy and safety of filgotinib. This article is a critical review of all these studies with focus on the therapeutic efficacy in RA. The aim is to display the data that could allow the approval of these new drugs for the treatment of RA (upadacitinib has been already approved in most of the markets around the world).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available